Contrasting Adynxx (OTCMKTS:ADYX) and Anika Therapeutics (NASDAQ:ANIK)

Adynxx (OTCMKTS:ADYX) and Anika Therapeutics (NASDAQ:ANIK) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, dividends, earnings and risk.

Institutional & Insider Ownership

91.5% of Anika Therapeutics shares are held by institutional investors. 17.4% of Adynxx shares are held by insiders. Comparatively, 7.9% of Anika Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Adynxx and Anika Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adynxx	N/A	N/A	N/A
Anika Therapeutics	-59.40%	-2.22%	-1.75%

Valuation & Earnings

This table compares Adynxx and Anika Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adynxx	N/A	N/A	N/A	N/A	N/A
Anika Therapeutics	$119.91 million	1.74	-$82.67 million	($3.85)	-3.82

Adynxx has higher earnings, but lower revenue than Anika Therapeutics.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Adynxx and Anika Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adynxx	0	0	0	0	0.00
Anika Therapeutics	0	1	1	1	3.00

Anika Therapeutics has a consensus price target of $21.67, indicating a potential upside of 47.49%. Given Anika Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Anika Therapeutics is more favorable than Adynxx.

Risk and Volatility

Adynxx has a beta of 2.67, suggesting that its stock price is 167% more volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Summary

Anika Therapeutics beats Adynxx on 6 of the 11 factors compared between the two stocks.

About Adynxx

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

About Anika Therapeutics

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company’s joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.